Sitagliptin reduces the urine albumin‐to‐creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate 西格列汀通过降低2型糖尿病患者的血压以及估算的肾小球滤过率来减少尿白蛋白/肌酐的比值

Abstract

Sitagliptin reduces the ACR through decreasing both blood pressure and eGFR, with no correlation with a decrease in HbA1c over a 3-month period. These results may reflect the direct action of sitagliptin on the kidneys.

The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial

“…When sitagliptin was administered, the bigger reduction of urinary albumin was observed in the cases who had the greater albuminuria at the baseline [40]. Based on other reports, administration of sitagliptin in human T2DM patients with nephropathy was followed by the initial drop of eGFR levels, and subsequently, the renal function was stabilized [43,44].…”

“…In fact, human clinical studies reported that sitagliptin had reduced albuminuria in many T2DM patients with nephropathy [39][40][41][42]. When sitagliptin was administered, the bigger reduction of urinary albumin was observed in the cases who had the greater albuminuria at the baseline [40].…”

Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence study

“…ACCEPTED MANUSCRIPT 9 albuminuria unrelated to changes in HbA1c) 15 . Our results are based on observational data that reflects clinical practice in Israel and are in line with previous studies 16,17 assessing the effect of sitagliptin on urinary albumin excretion.…”

“…Slowing of disease progression can be achieved through both glycemic and blood pressure control. 4,5 Recently, there have been studies showing a possible beneficial effect of incretin-based therapies on the kidneys [6][7][8][9] , in addition to the independent effect on hyperglycemia.…”

Incretin-based therapy: renal effects

“…Небольшие по объему пилотные иссле-дования показали возможность снижения альбуминурии у больных СД2 на фоне терапии ситаглиптином [82][83][84]. Прослежена взаимосвязь выраженности антиальбуми-нурического эффекта препарата с исходной величиной альбуминурии: наиболее заметное снижение ЭАМ про-слеживалось у больных с макроальбуминурией [82,85].…”